Abstract
Background: Despite the rapid growth of fluorescence imaging, accurate sampling of tissue sections remains challenging. Development of novel technologies to improve intraoperative assessment of tissue is needed. Methods: A novel contact probe-based fluorescence dosimeter device, optimized for IRDye800CW quantification, was developed. After evaluation of the device in a phantom setup, its clinical value was defined ex vivo in patients with head and neck squamous cell carcinoma who received panitumumab-IRDye800CW. Results: Ten patients were enrolled with a total of 216 data points obtained. Final histopathology showed tumor in 119 spots and normal tissue in 97 spots. Fluorescence-to-excitation ratios in tumor tissue were more than three times higher than those in normal tissue. The area under the curve was 0.86 (95% CI: 0.81-0.91) for tumor detection. Conclusions: Fluorescence-guided tissue preselection using a fluorescence dosimeter could have substantial impact on tissue sampling for frozen section analysis and potentially reduce sampling errors.
Original language | English |
---|---|
Pages (from-to) | 59-66 |
Number of pages | 8 |
Journal | Head and Neck |
Volume | 42 |
Issue number | 1 |
Early online date | 1 Oct 2019 |
DOIs | |
Publication status | Published - Jan 2020 |
Bibliographical note
Funding Information:This work was supported in part by the Stanford Comprehensive Cancer Center, the Stanford University School of Medicine Medical Scholars Program, the Netherlands Organization for Scientific Research (Rubicon; 019.171LW.022), the National Institutes of Health and the National Cancer Institute (R01CA190306), and the Stanford Molecular Imaging Scholars (SMIS) program (T32 CA118681).
Publisher Copyright:
© 2019 Wiley Periodicals, Inc.
Funding
This work was supported in part by the Stanford Comprehensive Cancer Center, the Stanford University School of Medicine Medical Scholars Program, the Netherlands Organization for Scientific Research (Rubicon; 019.171LW.022), the National Institutes of Health and the National Cancer Institute (R01CA190306), and the Stanford Molecular Imaging Scholars (SMIS) program (T32 CA118681).
Funders | Funder number |
---|---|
Netherlands Organization for Scientific Research | 019.171LW.022 |
Stanford Comprehensive Cancer Center | |
Stanford Molecular Imaging Scholars | T32 CA118681 |
Stanford University School of Medicine Medical Scholars Program | |
National Institutes of Health | |
National Cancer Institute | R01CA190306, T32CA118681 |
National Cancer Institute |
Keywords
- EGFR
- fluorescence dosimetry
- fluorescence-guided tissue preselection
- head and neck cancer
- panitumumab